News Sinopharm Group Co. Ltd.

Equities

1099

CNE100000FN7

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-16 am EDT			5-day change	1st Jan Change
19.54 ^HKD	-0.91%		-2.20%	-4.45%

Apr. 10	Chinese FDA Grants Marketing Approval for Shyndec Subsidiary's Drug Raw Materials	MT
Mar. 27	China Production Bases of Shyndec Pharmaceutical's Unit Gets Compliance Certification from Australian Regulator	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Chinese FDA Grants Marketing Approval for Shyndec Subsidiary's Drug Raw Materials	Apr. 10	MT
China Production Bases of Shyndec Pharmaceutical's Unit Gets Compliance Certification from Australian Regulator	Mar. 27	MT
Sinopharm's Attributable Profit Jumps in 2023 on Higher Revenue	Mar. 24	MT
Sinopharm Group Co. Ltd. Proposes Final Dividend of for the Financial Year Ended 31 December 2023, Payable on 13 August 2024	Mar. 24	CI
Sinopharm Group Co. Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 24	CI
China Stocks Muted at Close as Recovery Optimism Fades; Sinopharm Jumps 6% on Upbeat 2023 Earnings	Mar. 21	MT
Sinopharm's 2023 Profit Climbs 9%; Shares Up 6%	Mar. 21	MT
US Inflation, Light News Flow Churns Asian Stock Markets	Mar. 13	MT
Sinopharm Group Co. Ltd. Announces Change of Registered Address	Mar. 12	CI
Nomura Adjusts Sinopharm Group’s Price Target to HK$32.39 Form HK$33.31, Keeps at Buy	Mar. 11	MT
China Traditional Chinese Medicine's Stock Bolts on Privatization Offer	Feb. 22	MT
China stocks extend gains led by coal, AI; HK shares up	Feb. 22	RE
Hong Kong Stocks Hover Near Two-Month Highs Amid Mixed Corporate Earnings	Feb. 22	MT
China stocks jump with AI shares leading on Nvidia forecast; HK shares flat	Feb. 21	RE
Sinopharm offers to take China-TCM private in nearly $3 bln deal	Feb. 21	RE
Shyndec Pharma Unit's Cefotaxime Sodium for Injection Passes Drug Regulator's Consistency Evaluation	Feb. 20	MT
Cancer Drug of Shyndec Pharma's Unit Passes Drug Regulator's Evaluation	Feb. 20	MT
Shyndec Pharma Unit Obtains Antihistamine Marketing Rights for 7.7 Million Yuan	Jan. 03	MT
Sinopharm to Renew Financial Services Deal with Affiliate	Dec. 28	MT
Hutchmed China renews deals with "substantial" shareholders	Dec. 21	AN

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Sinopharm Group Co. Ltd.

Equities

1099

CNE100000FN7

Summary

Filters